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Chronic  pain  is a life  altering  condition  and  common  among  elderly  persons.
Buprenorphine  could  be  a suitable  pain  treatment  for  elderly  persons  in Sweden.
Both  UK  and  Swedish  EQ-5D  weights  show  improved  HRQoL  from  buprenorphine  treatment.
Buprenorphine  is  cost-effective  for  patients  aged  >50  with  moderate  chronic  pain.
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Background  and  aims:  Chronic  pain  is  a life altering  condition  and  common  among  elderly  persons.  The
7-day  buprenorphine  patch  could  be  a suitable  treatment  for managing  chronic  pain  of  moderate  severity
in  elderly  patients  in Sweden.
The  objective  of this  analysis  was to  investigate  the  cost-effectiveness  of  the  7-day  buprenorphine
patch,  versus  no treatment,  in patients  >50 years  old who  suffer  from  moderate  pain  in  a health  economic
perspective.  An  additional  aim  was  to evaluate  how  the  cost-effectiveness  is  affected  by  the  choice  of
EQ-5D  weights.
Methods:  The  annual  treatment  cost  and  the potential  gains  in  health-related  quality  of life  (HRQoL)
of  buprenorphine,  compared  to no  treatment,  were  evaluated.  Original  EQ-5D  data  were  collected  from
four clinical  reference  studies  at baseline  and  at  the  ﬁnal  visit.  Treatment  effects  on HRQoL  were  then
assessed  using  both  UK and  Swedish  EQ-5D  weights.  Annual  treatment  costs  were  calculated  based  on
costs  of  physician  visits  and  pharmaceuticals.
The optimal  treatment  dose  was  10–15 g/h  and  the  analysis  was  hence  performed  on  both  a  10-  and
a  15  g/h  buprenorphine  patch.
Results: The  analysis  of  buprenorphine  treatment  resulted  in  improved  HRQoL  in  all  reference  studies,
irrespective  of choice  of  EQ-5D  weight  set.  The  change  in quality  adjusted  life  years  (QALYs)  varied  with  a
gain of  0.042–0.118  using  the  UK  weights  and  0.020–0.051  with  the  Swedish  weights.  The  average  annual
treatment  cost  was  SEK  14  454  for the 10 g/h  patch  and SEK  17  017  for  the  15  g/h  patch,  while  cost  for
the  no-treatment  alternative  was  SEK  9 960.  The  base  case  incremental  cost-effectiveness  ratios  (ICER)
with  the  UK  weights  were  SEK  40 000–SEK  170 000  and SEK  90  000–SEK  350 000  when  applying  the
Swedish  weights.  The  corresponding  ICER-span  in  the sensitivity  analysis  was  SEK  15  000–SEK  400  000
when  applying  the  UK  weights  and  SEK  30 000–SEK  840 000  with  the Swedish  weights  (SEK  100  is about
D  11).
Conclusions:  The  results  imply  that the  7-day  buprenorphine  patch  may  be a cost-effective  treatment  of
moderate  chronic  pain  in  patients  over  50 years  of  age.  The  UK  and  the Swedish  EQ-5D  weights  generated
vastly  different  HRQoL  estimates  but buprenorphine  remains  cost-effective  regardless  choice  of  weight
set.
DOI of refers to article: http://dx.doi.org/10.1016/j.sjpain.2014.09.003.
Abbreviations: EQ-5D, EuroQoL 5-dimension quality of life instrument; HRQoL, health-related quality of life; ICER, incremental cost-effectiveness ratio; NBHW, the
ational Board of Health and Welfare; OA, osteoarthritis; QALY, quality adjusted life year; RCT, randomized clinical trial; TLV, the Dental and Pharmaceutical Beneﬁts Agency
the  Swedish reimbursement authority).
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Implications:  Buprenorphine  is  a treatment  alternative  that  could  be  included  in the  Swedish  reimburse-
ment system,  although  the  substantial  different  HRQoL  estimates  call  for clear  guidelines  regarding  the
applicability  of each  weight  regimen.
© 2014  The  Authors.  Published  by  Elsevier  B.V. This is  an  open  access  article  under the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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lected in all reference studies, none of them applied EQ-5D weights
or presented any in-depth HRQoL results nor did they explore the. Introduction
Chronic pain is a common and life-altering condition. The preva-
ence has been estimated to be 19 percent in the adult population
n Europe, a fraction that increases with age [1]. Yet treatment
f chronic pain remains complex, especially in older patients
ho face an ample risk of side effects [2]. Thus, the availabil-
ty of an efﬁcient analgesic therapy that minimizes side effects is
ssential [3].
Pain is typically divided into three levels of severity; mild, mod-
rate, and severe [4]. The choice of analgesic treatment depends on
he severity level. Paracetamol is the primary choice when treating
hronic pain but is limited to a maximum dose of 3–4 grams per
ay due to potential side effects, primarily hepatic events [2,5]. For
atients with moderate pain the maximal paracetamol dose often
rovides insufﬁcient pain relief. In elderly patients the second line
ain treatment is opioids [6].
Due to a severe risk of opioid side effects for patients over
he age of 65 the treatment recommendations for chronic pain
rom the Swedish National Board of Health and Welfare (NBHW)
re cautious regarding most opioids for elderly patients [2]. Both
OX inhibitors and tramadol, in addition to excessive utilization of
aracetamol, are related to increased risks for side effects and are
herefore viewed as risky treatments for elderly. Buprenorphine
an be administered in low doses, which limits the risk of side
ffects, and could therefore be a suitable second line pain treatment
n Sweden for elderly patients when the maximal dose of paraceta-
ol  provides insufﬁcient pain relief. The health economic analysis
herefore focuses on the cost-effectiveness of buprenorphine in
atients >65 years of age with moderate chronic pain.
This analysis is based on the effect of treatment on health-
elated quality of life (HRQoL) from published studies on
uprenorphine and provides an estimation of treatment costs.
n cost-effectiveness analyses both HRQoL gains and costs of a
uggested treatment regimen are compared to the best available
reatment alternative. As the NBHW is cautious regarding opioids
part from buprenorphine when treating patients >65 with moder-
te chronic pain, the comparator is no treatment. The no-treatment
lternative is deﬁned as no opioid treatment, i.e. the maximum
aracetamol dose of 4 g per day.
HRQoL is often measured through the generic EuroQol instru-
ent EQ-5D. EQ-5D weights based on interviews of the UK
opulation [7] has been the standard application in Sweden for
any years [8,9] according to recommendations by the Swedish
eimbursement authority the Pharmaceutical Beneﬁts Board (TLV)
10]. In the UK interviews, respondents were asked to rank dif-
erent health states using a hypothetical health approach [7]. In
013, a Swedish study reassigned the EQ-5D weights based on a
wedish general population health survey. Here, individuals were
sked to value their current health state, using an experienced-
ased approach [8].
The objective of this analysis was to investigate the cost-
ffectiveness of a 7-day buprenorphine patch, versus no-treatment,
n patients over >50 years of age with moderate chronic pain.
n additional aim was to evaluate how the cost-effectiveness is
ffected by the choice of EQ-5D weights.2. Materials and methods
2.1. Treatment and sample population
Buprenorphine is a synthetic opioid analgesic available in the
form of transdermal patches. The patches are administered every
7th day and are available in three strengths (5, 10 and 20 g/h) that
allows for individually adjusted treatment [3,11–14].
The present analysis is based on four clinical trials that evaluated
buprenorphine’s efﬁcacy and effects on HRQoL [11–14]. All studies
consider patients with moderate to severe chronic osteoarthritis
(OA) pain of the hip and/or knee. In three of the studies patients
were randomly assigned to either buprenorphine treatment or
a control group, where the control group was treated with tra-
madol [12], co-codamol [13] or placebo [11]. In the fourth study all
patients were treated with buprenorphine [14]. The clinical stud-
ies on which this analysis is based are hereafter referred to as the
reference studies. The reference studies are summarized in Table 1.
The reference studies provide evidence of signiﬁcant treat-
ment effects with favourable global impression of pain relief for
buprenorphine treatment, or conﬁrm a non-inferiority assump-
tion, irrespective of patient age [11–14]. Other previous studies
have indicated that buprenorphine has a good tolerability proﬁle
and clinical evidence of tolerance development is lacking, imply-
ing that dose escalations (and consequent escalation of side effects)
are unlikely [3]. Furthermore, buprenorphine is an appropriate
treatment of elderly patients as it does not require any adjust-
ment of treatment dose for patients with impaired kidney function
[13,15,16]. Buprenorphine could therefore be more attractive than
other strong opioids in patients with renal failure.
Although buprenorphine is an opioid that is associated with a
risk of opioid side effects, it has a reduced risk proﬁle in compar-
ison with other opioids that have proven to be clinically effective
[5]. Some of the side effects that are traditionally associated with
opioid treatment are severe and may  cause health decrements,
e.g. dizziness and risk of falling [5,6,17]. Yet, the unsuitability
of other available opioids mainly applies to patients over 65
years of age with increased risk of side effects. Still a combined
cost-effectiveness analysis for patients over 50 years of age was
performed. The combined analysis could be motivated by previous
studies that show similar pharmacokinetics and pharmacodynam-
ics for buprenorphine in all patients over the age of 50 [12,18]. Two
of the reference studies included patients younger than 50 years
of age, but these patients were excluded from the present analy-
sis [11,12]. The other two  reference studies included patients older
than 50 and 60 years of age, respectively [13,14].
2.2. Health-related quality of life
All four reference studies used the generic EuroQol instrument
EQ-5D to assess HRQoL [11–14]. Although EQ-5D data was  col-treatment effect on HRQoL. Therefore, analyses of the original EQ-
5D data collected in each reference study were performed, applying
both the UK and the Swedish EQ-5D weights.
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Table  1
Patient characteristics and background data of the reference studies.
Study descriptives Karlsson and Berggren [12] Breivik et al. [11] Conaghan et al. [13] Karlsson et al. [14]
N 134 199 220 122
Age,  mean 64 63 71 55 vs. 80
Gender,  female (%) 76 (57) 136 (68) 145 (66) 75 (61.5)
Type of pain Osteoarthritis Osteoarthritis Osteoarthritis Osteoarthritis
Initial  pain severity ≥4 on BS-11 pain scale
when using 4 g/day
paracetamol
Grade II–IV osteoarthritis of the hip
or knee, deﬁned by the Kellgren
and Lawrence scale, while on a
NSAID or a coxib
≥5 on the BS-11 pain scale
when taking the maximum
tolerated dose of
paracetamol
≥4 on BS-11 pain scale
when using 2–4 g/day
paracetamol
Treatment allocation 7-day buprenorphine
patches (n = 69), Tramadol
tablets (n = 65)
7-day buprenorphine patches
(n  = 100), Placebo patches (n = 99)
7-day buprenorphine
patches (n = 110),
Co-codamol tablets
(n = 110)
7-day buprenorphine
patches (N = 122)
Inclusion criteria ≥18 years of age with
diagnosed OA of hip and/or
knee
>40 years of age, at least moderate
radiographic OA changes, at least
moderate pain in hip and/or knee
while on NSAID or a coxib
≥60 years of age with
diagnosed OA of the hip
and/or knee
≥50 years of age with OA,
moderate to severe chronic
pain
Previous treatment Paracetamol 4 g/day NSAID or a coxib Maximum tolerated dose
of paracetamol
Non-opioid analgesic
Rescue medication Paracetamol Paracetamol Ibuprofen Paracetamol
Follow-up 12 weeks 28 weeks 12 weeks 12 weeks
Countries Sweden Denmark, Finland, Norway, UK Sweden
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Unit costs for pharmaceuticals and physician visits were col-
lected from ofﬁcial Swedish price lists [15,20]. All unit costs are
expressed in 2013 SEK and presented in Table 2.
Table 2
Unit costs of physician visits and pharmaceuticals (in 2013 SEK). SEK 100 was about
D  11.
Resources Unit cost
Primary care visit 1 386
Specialist visita 1 434
Buprenorphine 5 g 49
Buprenorphine 10 g 86
Buprenorphine 15 gb 135
Buprenorphine 20 g 154
Paracetamol (lowest price), 500 mg 0.53Sweden
EQ-5D has ﬁve dimensions (mobility, self-care, usual activities,
ain/discomfort, and anxiety/depression) and each dimension has
hree levels of severity corresponding to no problems, some prob-
ems, and extreme problems. This allows the generation of 243 (35)
ossible combinations, i.e. health states [19]. Each of the 243 EQ-5D
ealth states are assigned a value on a scale from 1 (perfect health)
o 0 (death). The more desirable the health state, the higher the
scribed value. Negative values can thus be considered to corre-
pond to health states worse than death [19]. A change in health is
hen quantiﬁed by its corresponding change in EQ-5D value.
At the ﬁnal visit of each reference study, patients treated with
uprenorphine were assumed to have reached their individual
ptimal pain relief, i.e. their optimal HRQoL level. The difference in
Q-5D estimates between the baseline visit and the ﬁnal visit was
herefore used as a measure of the treatment effect of buprenor-
hine on HRQoL. These HRQoL changes were estimated for each
eference study and are referred to as gains in quality adjusted life
ears (QALYs).
Patients were allowed paracetamol during the screening phase
nd as co-administered rescue medication in three of the four refer-
nce studies [11,12,14]. The forth study allowed ibuprofen instead
13]. The EQ-5D estimate at baseline is thus assumed to corre-
pond to the HRQoL when treated with paracetamol. As it is likely
hat HRQoL does not change under constant treatment of a chronic
isease this analysis assumes that the HRQoL of the no-treatment
lternative is constant over time, i.e. the changes in HRQoL of the
o-treatment alternative is set to zero.
All statistical analyses of the EQ-5D data were performed using
TATA 13 (StataCorp. 2013. Stata Statistical Software: Release 13.
ollege Station, TX: StataCorp LP).
.3. Treatment costs
Treatment costs were estimated for a 12-month period, includ-
ng costs for drugs and physician visits for the two  evaluated
lternatives; the 7-day buprenorphine patch and the no-treatment
lternative.Pharmaceutical costs were calculated based on the reported
ptimal treatment dose of buprenorphine in each study plus co-
dministration of rescue medication (paracetamol, assuming the
aximum dose of 4 g per day) [11–14]. Two of the referencestudies present optimal buprenorphine doses and they exclusively
fall in the range 10–15 g/h. Consequently the base case cost cal-
culation of buprenorphine treatment considers both a 10- and a
15 g/h dose. The no-treatment alternative was assumed to be the
maximum dose of paracetamol, 4 g per day. Thereby, the assumed
use of rescue medication is equivalent to the no-treatment alter-
native.
Since no information regarding the quantity of annual physi-
cian visits was  available in any of the publications six physician
visits were assumed irrespective of treatment alternative. The six-
visit assumption was based on the need of individualized opioid
treatment, which requires continuous physician visits [6]. The
assumption was  strengthened by a European study of chronic pain
that stated that 60 percent of all pain patients made between 2 and
9 medical visits during 6 months, converting to 4–18 visits per year
[1]. An average of six annual physician visits seems an appropri-
ate, or even conservative, assumption. Throughout the analysis 70
percent of the physician visits were allocated to primary care while
the remaining 30 percent was assumed to be specialist visits. The
70/30 allocation is according to estimates of the European study of
chronic pain [1]. In the base case analysis of six annual physician
visits, the 70/30 allocation correspond to four primary care visits
and two  specialist visits per year (4/2).a An average cost of specialist visits at a rheumatology clinic (SEK 1 685) and an
orthopaedic clinic (SEK 1 183).
b Combination of buprenorphine 5 g/h and buprenorphine 10 g/h (SEK 86 + SEK
49).
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.4. Incremental cost-effectiveness ratio
An incremental cost-effectiveness ratio (ICER) is the ratio of a
hange in treatment cost induced by implementation of a new
reatment alternative relative to the change in treatment effect,
.e. HRQoL [21]. The ICER hence translates into the cost per gained
ealth effect with the new treatment compared to its alternative. In
he present analysis the effects are measured in gained QALYs and
he costs refer to treatment costs. Thus, the ICERs are calculated as:
CER = Costbuprenorphine − Costno-treatment
Effectbuprenorphine − Effectno-treatment
EQ-5D data retrieved from each reference study were evaluated
nd the corresponding QALY gain from buprenorphine treatment
as estimated. The reference studies that generated the largest and
mallest QALY gains were then used as a proxy range of the true gain
n QALYs from buprenorphine treatment. The assessed QALY range
as then applied in the cost-effectiveness calculations in order to
stablish the minimum and maximum ICER.
.5. Sensitivity analysis
In order to evaluate the robustness of the base case results
 number of sensitivity analyses were conducted by varying the
ncertain parameters; physician visits, buprenorphine dosage and
osts of pharmaceuticals.
The annual physician visits were varied between 4, 10 and 13
or buprenorphine treatment. Keeping the 70/30 visit allocation
esulted in a primary-/specialist visit variation as 3/1, 7/3 and 9/4.
he number of visits for the no-treatment alternative was  ﬁxed at
ix.
Additionally, a buprenorphine dose of 20 g/h following the
ase case visit allocation 4/2 was included. The 20 g/h dose, falling
utside the optimal-dose range, constitutes a sensitivity analysis in
tself and the physician visits were thus not varied for this treatment
lternative.
A supplementary sensitivity analysis was performed on the no-
reatment alternative, where both pharmaceutical cost and number
f annual visits were varied.
. Results
.1. Health-related quality of life
Results from the analyses of HRQoL data from the reference
tudies, applying both the UK and the Swedish EQ-5D weights, are
resented in Table 3.
At baseline the UK weights estimate HRQoL to be approximately
alf as good as in a state of perfect health (0.505–0.592), while
he Swedish application value the baseline health at around three
uarters of a perfect health state (0.757–0.782).
Furthermore, the estimation with the UK weights shows that
uprenorphine treatment increases HRQoL with between 0.042
nd 0.118 QALYs annually, depending on reference study. The
stimation using Swedish weights is approximately half as large,
etween 0.020 and 0.051 QALYs.
The results indicate that buprenorphine treatment improves
RQoL, irrespectively of EQ-5D weight set.
.2. CostsTreatment costs, including both the cost of pharmaceuticals and
f physician visits, are presented in Table 4. In the base case the
nnual treatment cost of the no-treatment alternative sums to SEK
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dosage from SEK 14 454 for the 10 g/h patch to SEK 17 017 with
the 15 g/h patch.
3.3. Incremental cost-effectiveness
The ICER corresponds to the ratio of the additional cost of
buprenorphine treatment over the improvement in HRQoL com-
pared to the no-treatment alternative. The results of the base case
analysis are presented in Table 5.
The cost of treatment, and consequently the ICER, varies with
the buprenorphine dose. In the base case analyses, the maximum
ICER when applying the UK weights is SEK 168 000 per QALY gained,
while the corresponding number using the Swedish EQ-5D weights
is SEK 353 000.
The highest cost per QALY gained, i.e. the highest ICER value, cor-
responds to treatment with the more costly buprenorphine dose of
15 g/h. Conversely, the lowest ICER value is found when consid-
ering the lower treatment dose, buprenorphine 10 g/h.
The ICERs of the Swedish EQ-5D weights are approximately
twice the ICERs of the UK weights in all cases.
3.4. Sensitivity analysis
The results from the sensitivity analyses are presented in Table 5.
The ICER-span is between SEK 14 000 and SEK 400 000 with the
UK weights and stretch from SEK 33 000 to SEK 840 000 with the
Swedish weights.
The main part of the total treatment cost corresponds to costs of
physician visits. Consequently, a variation of the number of visits
has the highest inﬂuence on the ICERs. Again, the ICERs based on
the Swedish EQ-5D weights are approximately twice the ICERs esti-
mates using the UK weights.
Varying the annual physician visits of the no-treatment alter-
native between 4 and 13, when considering the lowest available
market price of paracetamol, produced annual treatment costs in
the range SEK 4 368–SEK 19 758 (not presented).
4. Discussion
This health economic analysis evaluates the cost-effectiveness
of buprenorphine patches compared to no-treatment in patients
with moderate chronic pain over the age of 50, in a Swedish set-
ting. HRQoL data was  collected from four clinical trials and annual
treatment costs were calculated based on costs of physician visits
and pharmaceuticals. The base case result present ICERs up to SEK
168 000 when applying the UK weights and SEK 353 000 with the
Swedish EQ-5D weights.
The ICER-values in the sensitivity analysis vary considerably,
even under a given EQ-5D weight set. The variation primarily
depends on the number of annual physician visits. The conservative
assumption potentially causes underestimated treatment costs in
absolute terms. Provided that the number of visits is kept equiva-
lent between the evaluated alternatives they will cancel out in the
comparison and are irrelevant to the ICER. In addition, patients in
the no-treatment group may  experience more pain and may  there-
fore be inclined to seek additional medical care. If so, the treatment
cost of the no-treatment alternative would increase and further
strengthen the cost-effectiveness of buprenorphine.
Sweden presently lacks general guidelines regarding the eco-
nomic worth of a QALY, although a threshold of SEK 655 000 has
been discussed [22]. However, the NBHW has quantiﬁed the cost
per QALY gained below SEK 100 000 as low and SEK 100 000–SEK
500 000 as moderate [23]. The results of the present analysis state
that the treatment effect of buprenorphine generally falls within
the moderate cost range. Thus, buprenorphine treatment could
be considered cost-effective since the ICER-values correspond to
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Table  3
Mean HRQoL outcomes based on EQ-5D data in patients >50 treated with buprenorphine.
Reference studies Na UK EQ-5D weights Swedish EQ-5D weights
Baseline visit Final visit Differenceb Baseline visit Final visit Differenceb
Karlsson and Berggren [12] 60 0.526 0.625 0.099 0.772 0.823 0.051
Breivik et al. [11] 84 0.592 0.634 0.042 0.782 0.801 0.020
Conaghan et al. [13] 102 0.516 0.632 0.116 0.757 0.785 0.028
Karlsson et al. [14] 116 0.505 0.623 0.118 0.758 0.804 0.046
a Patients where an EQ-5D assessment was available at both baseline and ﬁnal visit.
b Refers to the number of QALY gained.
Table 4
Annual costs of pharmaceuticals and physician visits (in 2013 SEK). SEK 100 was about D 11.
Pharmaceuticals Drug costs Cost of physician visitsb Total treatment cost
Units Drug cost Rescue medicationa
Paracetamol 4 g/day (lowest price), tablets 2 920 1 548 – 8 412 9 960
Buprenorphine 10 g/h, patches 52 4 494 1 548 8 412 14 454
Buprenorphine 15 g/hc, patches 52 7 057 1 548 8 412 17 017
phine
a
m
4
a
d
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5
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Ba Equivalent to the drug cost of paracetamol 4 g/day.
b Cost corresponding to 2 specialist visits and 4 primary care visits.
c Drug costs correspond to a combination of buprenorphine 5 g/h and buprenor
n accepted cost range [22,23], particularly since TLV recom-
ends use of the UK weights which generates ICERs below SEK
00 000.
Even though the UK and the Swedish HRQoL estimates in this
nalysis are based on the same EQ-5D data they generate rather
iverse estimates, both in absolute terms and regarding the beneﬁt
f health improvements. The variations are explained by the EQ-
D weights ascribing different HRQoL values to the same health
tates. Compared to the estimates using the Swedish weights, the
K weights generate considerably larger QALY gains which resultsn more cost-effective results.
The UK weights are based on a hypothetical health methodology
hile the Swedish weights were constructed using an experienced-
ased approach. A hypothetical health methodology asks the study
able 5
ase case and sensitivity analyses of incremental cost-effectiveness ratios (ICERs), 2013 p
Treatment Treatment cost buprenorphine Cost no
treatmentb
Drug costa Physician
visits
Total 
Buprenorphine 10 g/h
Base case, 6 visits 6 042 8 412 14 454 9 960 
4  visits 6 042 5 592 11 634 9 960 
10  visits 6 042 14 004 20 046 9 960 
13  visits 6 042 18 210 24 252 9 960 
Buprenorphine 15 g/h
Base case, 6 visits 8 605 8 412 17 017 9 960 
4  visits 8 605 5 592 14 197 9 960 
10  visits 8 605 14 004 22 609 9 960 
13  visits 8 605 18 210 26 815 9 960 
Buprenorphine 20 g/h
6 visits 9 556 8 412 17 968 9 960 
a Including cost of rescue medication.
b No treatment is deﬁned as paracetamol 4 g/day, 4 primary care visits and 2 specialist 10 g/h.
participants to rank a provided set of health states without the
participant necessarily having personal experience from any of the
presented health states. In an experienced-based approach, as that
of the Swedish study, the study participants are asked to rank their
own  current health in relation to a state of perfect health during a
given time period. It is a known fact that individuals tend to value
their own health state higher than the average population would
[24], which explains the higher estimates in absolute terms when
using the Swedish weights. Consequently, an impaired health state
such as chronic moderate pain is penalized harder, and an improved
health is rewarded more generously, with the UK weights. The vari-
ation in penalties are especially large regarding the pain dimension
[7,8]. Therefore the varying HRQoL outcomes between the weight
sets in the present analysis are according to expectation.
rices in SEK. SEK 100 was about D 11.
Cost
difference
ICERs based on UK
EQ-5D weights
ICERs based on Swedish
EQ-5D weights
QALY
gain
0.042
QALY
gain
0.118
QALY
gain
0.020
QALY
gain
0.051
4 494 107 000 38 085 224 700 88 118
1 674 39 857 14 186 83 700 32 824
10 086 240 143 85 475 504 300 197 765
14 292 340 286 121 119 714 600 280 235
7 057 168 024 59 805 352 850 138 373
4 237 100 881 35 907 211 850 83 078
12 649 301 167 107 195 632 450 248 020
16 855 401 310 142 839 842 750 330 490
8 008 190 667 67 864 400 400 157 020
 visits per year (SEK 9 960).
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The estimated differences between the UK and the Swedish EQ-
D weights in this analysis may  have considerable implications.
ealth care interventions found cost-effective using the UK weights
ill not necessarily be cost-effective with the Swedish regimen, or
ice versa. Suppliers of health care interventions are often required
o provide evidence of cost-effectiveness of their product when
pplying for reimbursement status, the results of which may  be
ffected by the choice of EQ-5D weights as shown in the present
nalysis. This in turn implies that the assessment by the reim-
ursement authority, i.e. what health care intervention reaches
he patients, may  be determined by the choice of EQ-5D weight
et.
Clinical studies show that the 7-day buprenorphine transder-
al  patch is an effective and well tolerated treatment alternative
or patients with moderate to severe chronic pain [11–14]. These
esults are supported by the ﬁndings of the present analysis where
uprenorphine improved HRQoL.
Opioid treatments are known to cause a high frequency of side
ffects [5]. In one of the reference studies about 30 percent of
he patients withdrew from the study due to side effects from
uprenorphine [11]. Still, buprenorphine is a more gentle treat-
ent than other available opioids [2]. Costs for treatment of opioid
ide effects, e.g. nausea, constipation, dizziness and falls are not
ncluded in the analysis due to lack of information on incidence and
reatment cost of complications. Including the costs of side effects
ould increase the cost of buprenorphine treatment compared to
he no-treatment alternative. Excluding the withdrawn patients in
he reference studies is also likely to effect the HRQoL results in
avour of buprenorphine. In addition, this analysis also excludes
dditional costs of potentially insufﬁcient pain management of the
o-treatment alternative, which may  lead to a need for excess uti-
ization of other health services. These exclusions, due to lack of
vailable data, are a weakness of the present analysis although
ach exclusion may  reduce the effect of the other. Additionally, the
ffects of unrelieved pain are assumed to be incorporated in the
RQoL assessment.
The buprenorphine doses applied in the present analysis were
ased on the average doses found in the reference studies, vary-
ng between 11 g/h and 14.5 g/h [11,14]. The highest average
ose was found in a patient aged 50–60 while the optimal dose
ere lower for patients aged 65 or older [14]. The absolute treat-
ent cost of buprenorphine may  thus be lower for the >65 than the
0–60 patient group and it is possible that buprenorphine becomes
ore cost-effective with age. It might therefore be a limitation that
he present analysis includes patients between 50 and 65 years of
ge even though similar pharmacokinetics and pharmacodynam-
cs have been reported for all patients older than 50 years of age
14,18].
It is also noteworthy that despite the implied cost-effectiveness
f buprenorphine for all analyzed patients, the treatment recom-
endations for patients aged 50–65 differ from those for patients
65. There are additional recommended treatment alternatives
vailable for the 50–65 age group that face lower risk of opioid
ide effects, and the present analysis does not rule out that there
re more cost-effective alternatives than buprenorphine for these
atients.
An advantage of buprenorphine, in addition to the cost-
ffectiveness implied in the results of this analysis, is that it does
ot require dose adjustment due to renal impairment in contrast
o strong opioids. This is partly why buprenorphine may  be a suit-
ble opioid treatment alternative. Since many elderly suffer from
enal impairment this may  further strengthen the attractiveness of
uprenorphine for this patient group.
Health economic analyses are performed on a group level, while
reatments such as pain management need to be individually
ailored for each patient. Therefore, the present analysis cannot rule
[rnal of Pain 6 (2015) 24–30 29
out that there may  be treatment alternatives that are more suitable
and more cost-effective than buprenorphine for individual patients,
e.g. patients who suffer from side effects of buprenorphine.
5. Conclusion
The ICERs of the 7-day buprenorphine patch fall within mod-
erate cost per QALY according to the NHBW categorization.
Buprenorphine can thus be considered a cost-effective treatment
of moderate chronic pain in older patients.
The UK and the Swedish EQ-5D weights generated vastly dif-
ferent HRQoL estimates but buprenorphine remains cost-effective
regardless choice of weight set.
6. Implications
Buprenorphine is a treatment alternative in clinical praxis that
could be included in the Swedish reimbursement scheme.
The substantial differences in the HRQoL estimates show that
the choice of EQ-5D weight is crucial for the results of a cost-
effectiveness analysis. Thus, the comparability of studies applying
separate weight sets is doubtful. Clear guidelines of the appropri-
ateness of each weight set are thus of utter importance.
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